MedTrace Logo

Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients

NCT01015274 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2018-07-11

No results posted yet for this study

Summary

The long-term objective of this research is to develop a non-invasive approach for early assessment of which patients are at high risk for future development of skeletal muscle atrophy. The investigators hypothesize that the rate constant for the terminal portion of the isotope decay curve following ingestion of a single oral dose of deuterated-3-methylhistidine (D-3MH) provides an accurate measure of this increased risk and that this rate constant can be measured non-invasively from timed spot urine samples.

Conditions

  • Cachexia

Sponsors & Collaborators

  • The University of Texas Medical Branch, Galveston

    lead OTHER

Principal Investigators

  • Morteza Janghorbani, Ph.D. · BIOCHEMANALYSIS CORPORATION

  • Melinda Sheffield-Moore, Ph.D. · University of Texas

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01015274 on ClinicalTrials.gov